Tags : University of Leeds

Original

LUNAC Therapeutics secures £2.65 million Series A investment led by

LUNAC Therapeutics spun out to develop next generation anticoagulants and announces Series A funding round Novel anticoagulants to minimise bleeding risk by targeting activated Factor XII Builds on a decade of academic research into Factor XII Investment round led by Epidarex Capital and University of Leeds Leeds, UK, 14 November 2019: LUNAC Therapeutics (LUNAC), a […]Read More